Aducanumab is a novel disease‐modifying anti‐amyloid‐beta (Aβ) human monoclonal antibody specifically targeted to the pathophysiology of Alzheimer's disease (AD). It was granted for treating AD in June 2021 by the United States Food and Drug Administration. We systematically analyzed available trial...
Research Assistant
AI chat, annotations, notes & similar papers
No comments yet
Be the first to share your thoughts!